Mechanisms for DNA‑damaging agent‑induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways

Park,Chul Min; Kawasaki,Yuki; Refaat,Alaa; Sakurai,Hiroaki

doi:10.3892/ol.2017.7532

Mechanisms for DNA‑damaging agent‑induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways

Authors:
- Chul Min Park
- Yuki Kawasaki
- Alaa Refaat
- Hiroaki Sakurai
View Affiliations

Affiliations: Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930‑0194, Japan
Published online on: December 5, 2017 https://doi.org/10.3892/ol.2017.7532
Pages: 1758-1762

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (CDDP) and doxorubicin (DOX) are chemotherapeutic drugs that trigger apoptosis by inducing DNA‑damage. A previous study using breast cancer cells demonstrated the negative feedback modulation of the epidermal growth factor receptor (EGFR) and receptor tyrosine‑protein kinase erbB‑2 (ErbB2) via extracellular signal‑regulated kinase (ERK)‑mediated phosphorylation of conserved Thr‑669 and Thr‑677 residues, respectively, in the juxtamembrane domain. In addition, CDDP has been identified to cause negative feedback inhibition of activated EGFR in lung cancer cells. In the present study, the role of phosphorylation in the feedback control of the ErbB2/ErbB3 heterodimer in human breast and gastric cancer cells was investigated. Phosphorylation of ErbB2 at Thr‑677 was induced by CDDP and DOX, which in turn reduced tyrosine autophosphorylation of ErbB2 and ErbB3. Treatment with trametinib, a mitogen‑activated protein kinase inhibitor that blocks ERK‑mediated Thr‑677 phosphorylation, and substitution of Thr‑677 to alanine, blocked the feedback inhibition of ErbB2 and ErbB3. In addition, these agents caused the degradation of ErbB proteins through the activation of p38 mitogen‑activated protein kinase (p38) and ERK. These results demonstrate that chemotherapeutic agents trigger ERK‑ and p38‑mediated post‑translational downregulation of ErbB receptors.

View Figures

View References

1	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sebastiana S, Settlemanb J, Reshkinc SJ, Azzaritia A, Bellizzia A and Paradisoa A: The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochim Biophys Acta. 1766:120–139. 2006.PubMed/NCBI
3	Schneider MR and Wolf E: The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 218:460–466. 2009. View Article : Google Scholar : PubMed/NCBI
4	Singh AB and Harris RC: Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal. 17:1183–1193. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sorkin A and Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 314:3093–3106. 2008.PubMed/NCBI
6	Avraham R and Yarden Y: Feedback regulation of EGFR signalling: Decision making by early and delayed loops. Nat Rev Mol Cell Biol. 12:104–117. 2011. View Article : Google Scholar : PubMed/NCBI
7	Pines G, Köstler WJ and Yarden Y: Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy. FEBS Lett. 584:2699–2706. 2010. View Article : Google Scholar : PubMed/NCBI
8	Park JW, Neve RM, Szollosi J and Benz CC: Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 8:392–401. 2008. View Article : Google Scholar : PubMed/NCBI
9	Ménard S, Tagliabue E, Campiglio M and Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 182:150–162. 2000. View Article : Google Scholar : PubMed/NCBI
10	Sato K, Shin MS, Sakimura A, Zhou Y, Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I and Sakurai H: Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci. 104:1315–1322. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kawasaki Y, Sakimura A, Park CM, Tomaru R, Tanaka T, Ozawa T, Zhou Y, Narita K, Kishi H, Muraguchi A and Sakurai H: Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. Sci Rep. 6:315022016. View Article : Google Scholar : PubMed/NCBI
12	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
13	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
14	Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 100:pp. 8933–8938. 2003; View Article : Google Scholar : PubMed/NCBI
15	Valabrega G, Montemurro F and Aglietta M: Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984. 2007. View Article : Google Scholar : PubMed/NCBI
16	Bailey TA, Luan H, Clubb RJ, Naramura M, Band V, Raja SM and Band H: Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog. 10:282011. View Article : Google Scholar : PubMed/NCBI
17	Bezlera M, Hengstlerb JG and Ullricha A: Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol. 6:516–529. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, Kadowaki S, Takahashi K, Sugiyama T, Kishi H and Muraguchi A: A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med. 15:1088–1092. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ozawa T, Piao X, Kobayashi E, Zhou Y, Sakurai H, Andoh T, Jin A, Kishi H and Muraguchi A: A novel rabbit immunospot array assay on a chip allows for the rapid generation of rabbit monoclonal antibodies with high affinity. PLoS One. 7:e523832012. View Article : Google Scholar : PubMed/NCBI
20	Sakurai H, Miyoshi H, Toriumi W and Sugita T: Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J Biol Chem. 274:10641–10648. 1999. View Article : Google Scholar : PubMed/NCBI
21	Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T and Saiki I: Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem. 278:36916–36923. 2003. View Article : Google Scholar : PubMed/NCBI
22	Refaat A, Aminullah, Zhou Y, Kawanishi M, Tomaru R, Abdelhamed S, Shin MS, Koizumi K, Yokoyama S, Saiki I and Sakurai H: Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells. Biochem Biophys Res Commun. 458:856–861. 2015. View Article : Google Scholar : PubMed/NCBI
23	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
24	Nishimura M, Shin MS, Singhirunnusorn P, Suzuki S, Kawanishi M, Koizumi K, Saiki I and Sakurai H: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol. 29:5529–5539. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK and Moore RG: Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers. Sci Rep. 5:159112015. View Article : Google Scholar : PubMed/NCBI
26	Frey MR, Dise RS, Edelblum KL and Polk DB: p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J. 25:5683–5692. 2006. View Article : Google Scholar : PubMed/NCBI
27	Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V and Sullivan M: PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40(Database Issue): D261–D270. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS and Nyati MK: Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 70:2862–2869. 2010. View Article : Google Scholar : PubMed/NCBI
29	Benhar M, Engelberg D and Levitzki A: Cisplatin-induced activation of the EGF receptor. Oncogene. 21:8723–8731. 2002. View Article : Google Scholar : PubMed/NCBI
30	Winograd-Katz SE and Levitzki A: Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 25:7381–7390. 2006. View Article : Google Scholar : PubMed/NCBI
31	Boone JJ, Bhosle J, Tilby MJ, Hartley JA and Hochhauser D: Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther. 8:3015–3023. 2009. View Article : Google Scholar : PubMed/NCBI
32	Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P and Ménard S: Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer. 105:568–573. 2003. View Article : Google Scholar : PubMed/NCBI
33	Li X, Lu Y, Liang K, Liu B and Fan Z: Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res. 7:R589–R597. 2005. View Article : Google Scholar : PubMed/NCBI
34	De U, Chun P, Choi WS, Lee BM, Kim ND, Moon HR, Jung JH and Kim HS: A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. Int J Oncol. 44:167–176. 2014. View Article : Google Scholar : PubMed/NCBI